- Home
- APLT vs OAKU Comparison
APLT vs OAKU Comparison
Compare APLT & OAKU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- OAKU
- Stock Information
- Founded
- APLT 2016
- OAKU 2022
- Country
- APLT United States
- OAKU Canada
- Employees
- APLT N/A
- OAKU N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- OAKU Blank Checks
- Sector
- APLT Health Care
- OAKU Finance
- Exchange
- APLT Nasdaq
- OAKU Nasdaq
- Market Cap
- APLT 37.5M
- OAKU N/A
- IPO Year
- APLT 2019
- OAKU 2023
- Fundamental
- Price
- APLT $0.41
- OAKU $11.69
- Analyst Decision
- APLT Buy
- OAKU
- Analyst Count
- APLT 7
- OAKU 0
- Target Price
- APLT $6.10
- OAKU N/A
- AVG Volume (30 Days)
- APLT 1.9M
- OAKU 1.9K
- Earning Date
- APLT 05-20-2025
- OAKU 01-01-0001
- Dividend Yield
- APLT N/A
- OAKU N/A
- EPS Growth
- APLT N/A
- OAKU N/A
- EPS
- APLT N/A
- OAKU 0.03
- Revenue
- APLT $455,000.00
- OAKU N/A
- Revenue This Year
- APLT $1,768.13
- OAKU N/A
- Revenue Next Year
- APLT $361.28
- OAKU N/A
- P/E Ratio
- APLT N/A
- OAKU $456.23
- Revenue Growth
- APLT N/A
- OAKU N/A
- 52 Week Low
- APLT $0.30
- OAKU $10.77
- 52 Week High
- APLT $10.62
- OAKU $11.71
- Technical
- Relative Strength Index (RSI)
- APLT 48.67
- OAKU 75.49
- Support Level
- APLT $0.39
- OAKU $11.60
- Resistance Level
- APLT $0.49
- OAKU $11.71
- Average True Range (ATR)
- APLT 0.04
- OAKU 0.00
- MACD
- APLT 0.01
- OAKU -0.00
- Stochastic Oscillator
- APLT 55.40
- OAKU 0.00
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.